Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment

Table 1 Characteristics of AV-GBM-1 products manufactured for patients (n = 60)

Variable	Mean	SEM	Median	Lower Limit	Upper Limit
Total irradiated tumor cells x 10⁶	14.0	1.2	11.0	0.78	63.4
Number of monocytes frozen x 10⁹	1.7	0.15	1.5	0.075	5.2
Number of DC to incubate with ATA x 10⁶	750	108	560	38	5720
Total DC-ATA per dose x 10⁶	7.9	0.68	7.4	0.26	27.0
% DC-ATA viable at cryopreservation	80.8	1.7	84.0	48.9	100

ISSN: 1756-9966